Board summary
Key figures
60,579
Registered population
54.9% aged 18–64
27.1%
Aged 65+
ICB 21.9% · England 17.9%
3.6%
Ethnic minority (non-White)
1.1% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 9.2% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
10,327
Hypertension register
+7.71% in 3 yrs · England +5.60%
473
SMI register
29.2% of Wealden's
913
COPD register
Reviews +18.12% in 3 yrs
Forecast to 2030
12,467
Hypertension patients, 2030
+2,140 on today
68.6%
QRISK ≥20% on statins, 2030
+4.84pp over 3 yrs
7.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
High-risk lipid therapy trails England.
Lipid-lowering therapy covers 57.5% of QRISK ≥ 20% patients (England 63.6%) and 63.0% of CKD patients (England 70.3%), which may reflect recall gaps.
COPD, dementia and LD registers shrank.
Over 2023 to 2025, COPD prevalence changed by -5.1% (England +2.6%), dementia -2.0% (England +6.0%), and learning disability -0.2% (England +5.4%), suggesting coding checks.
Strong blood pressure and COPD reviews.
Recent blood pressure recording reaches 93.3% (England 90.0%, Wealden 92.0%) and annual COPD reviews reach 80.3% (England 76.4%), showing strong review delivery.
Population, age and ethnicity
Registered patients aged 65+ reach 27.1%, exceeding England by 9.2 percentage points
Greater Wealden PCN serves 60,579 registered patients across 5 practices. The population is older than benchmarks: 27.1% (16,393 patients) are aged 65+, above Wealden (25.3%), NHS Sussex Integrated Care Board (21.9%) and England (17.9%). Patients aged 18–64 account for 54.9% and aged 0–17 account for 18.0%. Census usual residents in associated areas are 96.4% White, compared with Wealden (96.0%), NHS Sussex Integrated Care Board (91.0%) and England (81.1%), with a 3.6% ethnic minority share. This older age profile may increase frailty demand. Ethnicity reflects resident Census data, not GP registration.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Wealden local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wealden LA) | 2,246 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.6% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 62.6% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wealden LA) | 958 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wealden LA) | 8.6 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Registered patients in Core20 stand at 0.0% across an average deprivation decile of 7.4
The PCN has an average Index of Multiple Deprivation decile of 7.4 (Wealden 7.1, NHS Sussex Integrated Care Board 6.1, England 5.5). Across the PCN, 0.0% of registered patients live in Core20 areas (Wealden 1.7%, England 21.0%), yielding 0 estimated Core20 patients across 53 associated LSOAs. Captured practice deciles span from 6.5 at Herstmonceux Integrative Health Centre to 7.7 at The Meads Surgery. Zero Core20 representation indicates health inequalities work may need to target specific clinical cohorts or rural pockets rather than national area deprivation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
473
SMI register
0.77% recorded prevalence
339
Learning disability register
0.55% recorded prevalence
34
Care homes, 1,311 beds
In the PCN catchment
8.8%
Provide unpaid care
Wealden, Census 2021
Severe mental illness register prevalence is 0.8% (473 patients) and learning disability is 0.6% (339 patients), alongside 34 catchment care homes with 1,311 beds. Catchment bed counts do not confirm registered residents. With severe mental illness below England (1.0%) and learning disability matching England (0.6%), proactive annual health reviews and structured care-home outreach are key priorities to sustain.
Severe mental illness: physical health checks
Recorded SMI prevalence is 0.8% against 1.0% in England. Annual blood pressure checks reach 87.9% and BMI checks 86.5%, though Herstmonceux Integrative Health Centre recorded 69.0% for blood pressure. Published individual indicators cannot confirm full check completion.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
10,327
Hypertension register
+7.71%
Register growth, 3 yrs
Wealden +5.15% · England +5.60%
+5.89pp
BP control, under 80
≤140/90 · +3.23pp aged 80+
+2,140
More patients by 2030
Forecast 12,467 (19.60%)
Hypertension case-finding and control
Hypertension recorded prevalence is 16.9% (10,327 patients), below Wealden (17.7%) but above England (15.2%) and NHS Sussex Integrated Care Board (16.3%), with non-age-adjusted register gaps spanning -1,101 to +377 patients. A projection points to 12,467 patients by 2030, an increase of 2,140 (about 2,100), though its methodology is unverified. Recent blood pressure checks reach 93.3% (England 90.0%), and control to threshold is 69.4% (England 70.3%), with control in patients under 80 at 66.9% (England 67.8%). Blood pressure recording exceeds national levels while control slightly trails England, indicating clinical review could focus on treatment titration.
Lipids and statins
Lipid-lowering therapy reaches 57.5% for patients with QRISK ≥ 20% (England 63.6%, NHS Sussex Integrated Care Board 60.0%), 63.0% in chronic kidney disease (England 70.3%), and 79.9% in diabetes with cardiovascular disease (England 84.4%). Lower coverage across these cohorts could reflect recall gaps, which clinical register audits can test.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 119,062 | £2.00 | £2.42 | £1.86 | £238,124 |
| Cardiovascular (all), 2025 | 162,443 | £2.97 | £3.32 | £3.33 | £482,456 |
In 2026, the PCN prescribed 119,062 lipid-regulating drug items at £2.00 per item (England £1.86, Wealden £2.18, NHS Sussex Integrated Care Board £2.42). The PCN spends £16,669 more than at England's unit cost, across 119,062 items, but £50,006 less than at NHS Sussex Integrated Care Board's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+14.13%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.50%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 1.5% (913 patients; Wealden 2.0%, England 1.9%), and prevalence fell 5.1% over three years (Wealden +2.6%, England +2.6%). COPD reviews rose +18.1% (England +2.8%) to 80.3% (England 76.4%). Asthma prevalence is 7.1% (4,100 patients; England 6.6%), but review coverage is 62.1% against 63.5% in Wealden and 65.7% in England. This leaves 1,553 patients (about 1,600) without a recorded review.
Cancer register and children's immunisation
The cancer register records 3,114 patients (5.1% prevalence against 3.8% in England), growing +18.0% over 2023 to 2025 (England +9.0%). For childhood immunisations, age-5 MMR dose 1 reaches 95.6% (cohort 137), exceeding the 95.0% target. However, same-cohort MMR dose 2 drops 4.4 pp to 91.2%, while MMR dose 1 at 24 months is 88.4%. This drop-off indicates an operational need to strengthen pre-school recall before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In Greater Wealden PCN, recorded cancer prevalence is 5.1% (3,114 patients; England 3.8%), rising +18.0% over 2023 to 2025 (England +9.0%). Across the wider health system, 58.5% of cancers with a known stage in NHS Sussex ICB were diagnosed at stage 1 or 2 in 2022 (4,799 of 8,209; England 55.3%), below the 75.0% national ambition by 2028, requiring about 1,360 additional early-stage diagnoses each year. Known-stage completeness was 64.3% (8,209 of 12,766 registered cases; England 67.0%). These ICB figures describe wider health system staging rather than PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), East Sussex Healthcare NHS Trust achieved 67.0% on the 62-day cancer referral to treatment standard (standard 85.0%), below Maidstone and Tunbridge Wells NHS Trust (87.4%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%), but above University Hospitals Sussex NHS Foundation Trust (65.2%). The trust met the 28-day faster diagnosis standard at 84.2% (standard 75.0%) and the 31-day treatment standard at 98.2% (standard 96.0%). In Jul 2026, 6.5% waited 6+ weeks for MRI and 0.5% for CT (England 21.4% and 9.9%). These acute trust figures describe hospital provider performance, not PCN activity.
| Pathways within standard (%) | East Sussex Healthcare | Sussex | Maidstone and Tunbridge Wells | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 84.20 | 74.01 | 81.78 | 79.29 | 79.32 |
| 31-day treatment (96%) | 98.19 | 76.79 | 98.35 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 67.04 | 65.20 | 87.43 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Sussex Healthcare | Sussex | Maidstone and Tunbridge Wells | England |
|---|---|---|---|---|
| MRI | 6.48 | 5.62 | 0.92 | 21.40 |
| CT | 0.48 | 8.57 | 0.51 | 9.92 |
| Echocardiography | 21.94 | 0.39 | 2.57 | 28.48 |
| Colonoscopy | 0.74 | 39.35 | 19.80 | 30.83 |
| Gastroscopy | 0.31 | 20.02 | 24.03 | 29.02 |
| All 15 DM01 tests | 5.27 | 12.95 | 6.42 | 23.14 |
| Community services activity | East Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 100,740 | 309,615 |
| Referrals | 17,285 | 66,930 |
| Patients with a contact | 25,880 | 85,660 |
Community services (residents of East Sussex), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65 and over accounted for 68% of community service contacts among Wealden residents (68,465 of 100,740 contacts). This borough-level activity reflects community service contacts among older residents, although activity is not captured at PCN level.
Practice variation and patient experience
QOF vaccination achievement spans 80 pp across practices, from 20.0% to 100.0%
In 2025/26, QOF vaccination and immunisation achievement spans 80 pp across practices, from 20.0% at Buxted Medical Centre to 100.0% at The Meads Surgery (England 55.2%). Clinical-domain achievement is 72.4% at Herstmonceux Integrative Health Centre and 100.0% at The Meads Surgery (England 97.1%). This variation could reflect local recall workflows, testable by practice protocol audits.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| The Meads Surgery | 102 | 0.0 | 49.7% | 72.9% | 82.2% |
| Bird-in-eye | 127 | 0.0 | 55.4% | 84.6% | 80.8% |
| Wealden Ridge | 103 | 0.0 | 46.4% | 85.4% | 77.3% |
| Herstmonceux | 112 | 0.0 | 46.3% | 79.8% | 70.8% |
| Buxted | 123 | 0.0 | 27.5% | 55.0% | 63.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Seven of 25 compared measures trail England over three years, led by dementia
Across 25 compared measures, seven trail England over three years (2023 to 2025). Relative three-year register changes fell for dementia by 2.0% (England +6.0%), COPD by 5.1% (England +2.6%), and learning disability by 0.2% (England +5.4%), alongside slower growth in heart failure reviews (+5.2% versus England +8.7%). Conversely, review activity grew: COPD reviews rose +18.1% (England +2.8%) and asthma reviews rose +14.1% (England +4.4%). These diverging trends could reflect coding revisions or list turnover rather than deteriorating delivery, which clinical searches can clarify.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
COPD register
Learning disability register
Heart failure reviews
Diabetes HbA1c control
COPD reviews
Asthma reviews
Hypertension BP reading
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wealden | Asset | PCN | Wealden |
|---|---|---|---|---|---|
| Care homes (catchment) | 34 (1,311 beds) | n/a | Schools (catchment) | 63 | n/a |
| Children's centres | 1 | 2 | Places of worship | 92 | 161 |
| Libraries | 2 | 7 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | 2 | 2 | Day centres (VCS) | 1 | 6 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 29 | 40 | Primary academies | 4 | 8 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma review coverage is 62.1% across 4,100 patients, below Wealden (63.5%, 1.4 pp below) and England (65.7%, 3.6 pp below), leaving 1,553 patients (about 1,600) unreviewed. For discussion: practices could run a single-template asthma recall and offer flexible review slots to reach unreviewed patients. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
COPD and respiratory register validation
COPD prevalence is 1.5% (913 of 60,579 patients), below England (1.9%) and Wealden (2.0%), with a non-age-adjusted gap of +235 to +299 patients after falling 5.1% over 2023 to 2025. For discussion: practices could search for patients with repeated respiratory prescribing lacking a COPD code and review diagnostic pathways. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Lipid-lowering therapy recall in high-risk cohorts
Lipid-lowering therapy is 57.5% in QRISK ≥ 20% (England 63.6%, 6.0 pp below; ICB 60.0%), 63.0% in CKD (England 70.3%, 7.3 pp below), and 79.9% in diabetes with CVD (England 84.4%). Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older population proactive care review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Practice vulnerability register audit (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check review (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension therapy review (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Early cancer diagnosis pathway review (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · COPD and respiratory register validation (p12) | COPD register · COPD: QOF prevalence · Registered population | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · Lipid-lowering therapy recall in high-risk cohorts (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
